Clinical characteristics and social productivity levels of patients with malignant rheumatoid arthritis based on a nationwide clinical database in Japan: annual survey from 2003 to 2013

References

• Bevans M, Nadell J, Demartini F, Ragan C. The systemic lesions of malignant rheumatoid arthritis. Am J Med. 1954;16(2):197–211.
   PubMed Web of Science ®Google Scholar
• Aikawa T, Yoshizawa H. Rheumatoid vasculitis and malignant rheumatoid arthritis. Nippon Rinsho. 1985;43(10):2065–9.
   PubMedGoogle Scholar
• Matsumoto Y. The rheumatoid vasculitis and malignant rheumatoid arthritis(MRA). Nippon Rinsho. 2002;60(12):2408–16.
   PubMedGoogle Scholar
• Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019;170(1):ITC1–itc16.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.
   PubMed Web of Science ®Google Scholar
• Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology. 2014, ed. Osaka: Medical Review Co., Ltd.; 2014.
   Google Scholar
• Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, et al.; British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford). 2006;45(9):1167–9.
   PubMed Web of Science ®Google Scholar
• Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford). 2009;48(4):436–9.
   PubMed Web of Science ®Google Scholar
• Kishore S, Maher L, Majithia V. Rheumatoid vasculitis: a diminishing yet devastating menace. Curr Rheumatol Rep. 2017;19(7):39.
   PubMed Web of Science ®Google Scholar
• Makol A, Matteson EL, Warrington KJ. Rheumatoid vasculitis: an update. Curr Opin Rheumatol. 2015;. 27(1):63–70.
   PubMed Web of Science ®Google Scholar
• Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659–62.
   PubMed Web of Science ®Google Scholar
• Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore). 1981;60(4):288–97.
   PubMed Web of Science ®Google Scholar
• Kato E, Sawada T, Tahara K, Hayashi H, Tago M, Mori H, et al. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis. 2017;20(7):839–45.
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Dellaripa PF. Lung manifestations in the rheumatic diseases. Chest 2017;152(6):1283–95.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544–54.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, T2T Expert Committee, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7.
   PubMed Web of Science ®Google Scholar
• Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med. 1991;151(11):2249–54.
   PubMedGoogle Scholar
• Abel T, Andrews BS, Cunningham PH, Brunner CM, Davis JSt, Horwitz DA. Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes. Ann Intern Med. 1980;93(3):407–13.
   PubMed Web of Science ®Google Scholar
• Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76(3):377–84.
   PubMed Web of Science ®Google Scholar
• Makol A, Crowson CS, Wetter DA, Sokumbi O, Matteson EL, Warrington KJ. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology (Oxford). 2014;53(5):890–9.
   PubMed Web of Science ®Google Scholar
• Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002;41(10):1126–32.
   PubMed Web of Science ®Google Scholar
• Puéchal X, Miceli-Richard C, Mejjad O, Lafforgue P, Marcelli C, Solau-Gervais E, et al.; Club Rhumatismes et Inflammation (CRI). Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis. 2008;67(6):880–4.
   PubMed Web of Science ®Google Scholar
• Josselin L, Mahr A, Cohen P, Pagnoux C, Guaydier-Souquieres G, Hayem G, et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis. 2007;67(9):1343–6.
   Web of Science ®Google Scholar
• Assmann G, Pfreundschuh M, Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clin Exp Rheumatol. 2010;28(1 Suppl 57):81–3.
   PubMed Web of Science ®Google Scholar
• Puechal X, Gottenberg JE, Berthelot JM, Gossec L, Meyer O, Morel J, Investigators of the AutoImmunity Rituximab Registry, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry. Arthritis Care Res (Hoboken). 2012;64(3):331–9.
   PubMed Web of Science ®Google Scholar
• Hellmann M, Jung N, Owczarczyk K, Hallek M, Rubbert A. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47(6):929–30.
   PubMed Web of Science ®Google Scholar
• Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63 (Suppl 5):v1–58.
   PubMed Web of Science ®Google Scholar
• Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–6.
   PubMed Web of Science ®Google Scholar
• Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. Rheumatology (Oxford). 2017;56(8):1348–57.
   PubMed Web of Science ®Google Scholar
• Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19(3):353–9.
   PubMed Web of Science ®Google Scholar
• Fernández-Díaz C, Loricera J, Castañeda S, López-Mejías R, Ojeda-García C, Olivé A, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum. 2018;48(1):22–7.
   PubMed Web of Science ®Google Scholar
• Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003;30(10):2287–91.
   PubMed Web of Science ®Google Scholar
• Saint Marcoux B, Bandt MD,; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73(6):710–3.
   PubMed Web of Science ®Google Scholar
• Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S23–S9.
   PubMed Web of Science ®Google Scholar
• Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2012;87(8):739–45.
   PubMed Web of Science ®Google Scholar
• Nyhall-Wahlin BM, Petersson IF, Jacobsson C, Geborek P, Nilsson JA, Nilsson K, et al. Extra-articular manifestations in a community-based sample of patients with rheumatoid arthritis: incidence and relationship to treatment with TNF inhibitors. Scand J Rheumatol. 2012;41(6):434–7.
   PubMed Web of Science ®Google Scholar
• Negoescu AF, Tennekone D, Soljak MA, Abraham SM. Extraarticular manifestations of rheumatoid arthritis develop in patients receiving anti-tumor necrosis factor-α treatment: a retrospective chart review from a UK center. J Rheumatol. 2014;41(10):1944–7.
   PubMed Web of Science ®Google Scholar
• Richette P, Dieude P, Damiano J, Liote F, Orcel P, Bardin T. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol. 2004;31(10):2079–81.
   PubMed Web of Science ®Google Scholar
• Fujikawa K, Kawakami A, Hayashi T, Iwamoto N, Kawashiri SY, Aramaki T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol. 2010;20(1):86–9.
   PubMed Web of Science ®Google Scholar
• Theander L, Nyhall-Wahlin BM, Nilsson JA, Willim M, Jacobsson LTH, Petersson IF, et al. Severe extraarticular manifestations in a community-based cohort of patients with rheumatoid arthritis: risk factors and incidence in relation to treatment with tumor necrosis factor inhibitors. J Rheumatol. 2017;44(7):981–7.
   PubMed Web of Science ®Google Scholar
• Terreaux W, Masson C, Eschard JP, Bardin T, Constantin A, Dantec LL, et al. Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: data from the French registry REGATE. Joint Bone Spine. 2018;85(1):53–7.
   PubMedGoogle Scholar
• Tanaka E, Inoue E, Hoshi D, Shimizu Y, Kobayashi A, Sugimoto N, et al. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Mod Rheumatol. 2015;25(4):503–13.
   PubMed Web of Science ®Google Scholar
• Emery P, Smolen JS, Ganguli A, Meerwein S, Bao Y, Kupper H, et al. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. Rheumatology (Oxford). 2016;55(8):1458–65.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Winthrop K, O'Brien C, Ndlovu MN, de Longueville M, Haraoui B. Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. Arthritis Res Ther. 2017;19(1):276.
   PubMedGoogle Scholar
• Tanaka E, Inoue E, Yamaguchi R, Shimizu Y, Kobayashi A, Sugimoto N, et al. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan. Mod Rheumatol. 2017;27(2):227–36.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Schmidt D, Wagner U, Goronzy JJ. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum. 1998;41(5):817–22.
   PubMedGoogle Scholar